CFOK yields 25.00% · ABBV yields 3.06%● Live data
📍 ABBV pulled ahead of the other in Year 3
Combined, CFOK + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of CFOK + ABBV for your $10,000?
Community First Bancorporation operates as the bank holding company for Community First Bank that provides commercial banking products and services to personal and business customers. The company offers various deposit products, including checking accounts, NOW accounts, individual retirement accounts, time deposits, and money market accounts and certificates of deposit. It also provides commercial loans, including short term unsecured loans, short and intermediate term real estate mortgage loans, and loans secured by listed stocks, as well as loans secured by equipment, inventory, and accounts receivable; consumer loans, such as home equity improvement loans secured by first and second mortgages, personal expenditure loans, education loans, and overdraft lines of credit, as well as car, recreational vehicle, and boat loans; and debit and credit card services. In addition, the company offers direct deposit, foreign payment and currency exchange, electronic bill payment, remote check deposit, merchant, and other related services; internet and mobile banking services; and life, home, auto, health, and pet insurance products. It operates through eight full-service offices in Walhalla, Seneca, Anderson, Williamston, Westminster, and Greenville, South Carolina, as well as two in North Carolina; and loan production offices in Charlotte and Concord, North Carolina. Community First Bancorporation was founded in 1988 and is based in Walhalla, South Carolina.
Full CFOK Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.